NCT00972829View on ClinicalTrials.gov

Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia

PHASE4UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

March 31, 2011

Conditions
Hypercholesterolemia
Interventions
DRUG

Rosuvastatin

Rosuvastatin 10 or 20 milligrams once or twice a week

DRUG

Ezetimibe

Ezetimibe 5 or 10 milligrams

Trial Locations (1)

10468

RECRUITING

Bronx VA Medical Center, The Bronx

Sponsors
All Listed Sponsors
lead

Bronx VA Medical Center

FED

NCT00972829 - Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia | Biotech Hunter | Biotech Hunter